Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer
To date, various chemically synthesized and biosynthesized nanoparticles, or hybrid nanosystems and/or nanoplatforms, have been developed under the umbrella of nanomedicine. These can be introduced into the body orally, nasally, intratumorally or intravenously. Successfully translating hybrid nanopl...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1797099217570758656 |
|---|---|
| author | Thorat, ND Townley, HE Patil, RM Tofail, SAM Bauer, J |
| author_facet | Thorat, ND Townley, HE Patil, RM Tofail, SAM Bauer, J |
| author_sort | Thorat, ND |
| collection | OXFORD |
| description | To date, various chemically synthesized and biosynthesized nanoparticles, or hybrid nanosystems and/or nanoplatforms, have been developed under the umbrella of nanomedicine. These can be introduced into the body orally, nasally, intratumorally or intravenously. Successfully translating hybrid nanoplatforms from preclinical proof-of-concept to therapeutic value in the clinic is challenging. Having made significant advances with drug delivery technologies, we must learn from other areas of oncology drug development, where patient stratification and target-driven design have improved patient outcomes. This review aims to identify gaps in our understanding of the current strengths of nanomedicine platforms in drug delivery and cancer theranostics. We report on the current approaches of nanomedicine at preclinical and clinical stages. |
| first_indexed | 2024-03-07T05:20:35Z |
| format | Journal article |
| id | oxford-uuid:dec0cac0-be32-4d3b-a134-624c1c1dc507 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:20:35Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:dec0cac0-be32-4d3b-a134-624c1c1dc5072022-03-27T09:34:38ZComprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:dec0cac0-be32-4d3b-a134-624c1c1dc507EnglishSymplectic ElementsElsevier2020Thorat, NDTownley, HEPatil, RMTofail, SAMBauer, JTo date, various chemically synthesized and biosynthesized nanoparticles, or hybrid nanosystems and/or nanoplatforms, have been developed under the umbrella of nanomedicine. These can be introduced into the body orally, nasally, intratumorally or intravenously. Successfully translating hybrid nanoplatforms from preclinical proof-of-concept to therapeutic value in the clinic is challenging. Having made significant advances with drug delivery technologies, we must learn from other areas of oncology drug development, where patient stratification and target-driven design have improved patient outcomes. This review aims to identify gaps in our understanding of the current strengths of nanomedicine platforms in drug delivery and cancer theranostics. We report on the current approaches of nanomedicine at preclinical and clinical stages. |
| spellingShingle | Thorat, ND Townley, HE Patil, RM Tofail, SAM Bauer, J Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| title | Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| title_full | Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| title_fullStr | Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| title_full_unstemmed | Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| title_short | Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| title_sort | comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer |
| work_keys_str_mv | AT thoratnd comprehensiveapproachofhybridnanoplatformsindrugdeliveryandtheranosticstocombatcancer AT townleyhe comprehensiveapproachofhybridnanoplatformsindrugdeliveryandtheranosticstocombatcancer AT patilrm comprehensiveapproachofhybridnanoplatformsindrugdeliveryandtheranosticstocombatcancer AT tofailsam comprehensiveapproachofhybridnanoplatformsindrugdeliveryandtheranosticstocombatcancer AT bauerj comprehensiveapproachofhybridnanoplatformsindrugdeliveryandtheranosticstocombatcancer |